Inozyme Pharma, Inc.

NasdaqGS:INZY Stock Report

Market Cap: US$180.5m

Inozyme Pharma Valuation

Is INZY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INZY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INZY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INZY's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for INZY?

Key metric: As INZY is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for INZY. This is calculated by dividing INZY's market cap by their current book value.
What is INZY's PB Ratio?
PB Ratio2.2x
BookUS$82.79m
Market CapUS$180.51m

Price to Book Ratio vs Peers

How does INZY's PB Ratio compare to its peers?

The above table shows the PB ratio for INZY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.7x
KYTX Kyverna Therapeutics
0.6x-25.1%US$189.5m
NKTX Nkarta
0.4x-11.5%US$172.9m
TNYA Tenaya Therapeutics
1.7x61.5%US$188.5m
VSTM Verastem
16.1x25.4%US$178.0m
INZY Inozyme Pharma
2.2x-0.7%US$180.5m

Price-To-Book vs Peers: INZY is good value based on its Price-To-Book Ratio (2.2x) compared to the peer average (4.7x).


Price to Book Ratio vs Industry

How does INZY's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
INZY 2.2xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: INZY is expensive based on its Price-To-Book Ratio (2.2x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is INZY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INZY PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate INZY's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INZY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.81
US$18.75
+567.3%
51.7%US$43.00US$12.00n/a8
Nov ’25US$4.36
US$19.00
+335.8%
44.5%US$40.00US$13.00n/a8
Oct ’25US$5.02
US$19.00
+278.5%
44.5%US$40.00US$13.00n/a8
Sep ’25US$5.54
US$19.43
+250.7%
46.1%US$40.00US$13.00n/a7
Aug ’25US$5.41
US$20.00
+269.7%
47.5%US$40.00US$14.00n/a6
Jul ’25US$4.41
US$20.00
+353.5%
47.5%US$40.00US$14.00n/a6
Jun ’25US$4.82
US$19.43
+303.1%
45.9%US$40.00US$14.00n/a7
May ’25US$4.61
US$20.33
+341.1%
45.8%US$40.00US$14.00n/a6
Apr ’25US$7.31
US$21.00
+187.3%
42.4%US$40.00US$15.00n/a6
Mar ’25US$6.55
US$21.00
+220.6%
42.4%US$40.00US$15.00n/a6
Feb ’25US$5.64
US$21.00
+272.3%
42.4%US$40.00US$15.00n/a6
Jan ’25US$4.26
US$21.00
+393.0%
42.4%US$40.00US$15.00n/a6
Dec ’24US$3.85
US$21.00
+445.5%
42.4%US$40.00US$15.00n/a6
Nov ’24US$2.89
US$21.00
+626.6%
42.4%US$40.00US$15.00US$4.366
Oct ’24US$4.20
US$21.00
+400.0%
42.4%US$40.00US$15.00US$5.026
Sep ’24US$4.83
US$20.33
+321.0%
46.2%US$40.00US$12.00US$5.546
Aug ’24US$5.02
US$21.00
+318.3%
43.2%US$40.00US$13.00US$5.416
Jul ’24US$5.57
US$20.83
+274.0%
45.0%US$40.00US$11.00US$4.416
Jun ’24US$6.37
US$20.83
+227.1%
45.0%US$40.00US$11.00US$4.826
May ’24US$5.81
US$19.17
+229.9%
56.6%US$40.00US$6.00US$4.616
Apr ’24US$5.73
US$19.17
+234.5%
56.6%US$40.00US$6.00US$7.316
Mar ’24US$3.04
US$22.00
+623.7%
44.4%US$40.00US$12.00US$6.555
Feb ’24US$2.47
US$18.92
+665.9%
59.0%US$40.00US$4.50US$5.646
Jan ’24US$1.05
US$18.92
+1,701.6%
59.0%US$40.00US$4.50US$4.266
Dec ’23US$1.42
US$18.92
+1,232.2%
59.0%US$40.00US$4.50US$3.856
Nov ’23US$1.64
US$20.08
+1,124.6%
53.7%US$40.00US$4.50US$2.896

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies